home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 11/06/21

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn: Recent Data Warrants A Change In Game Plan

CytoDyn recently reported preliminary analysis from Leronlimab in mTNBC patients and NASH. I believe this data supports further development of Leronlimab in NASH and cancer indications. The recent data has provided me enough confidence to change my strategy. I am looking to start allo...
CYDY - CytoDyn posts preliminary results from mid-stage leronlimab NASH study

CytoDyn (OTCQB:CYDY) posts preliminary results from the first five patients treated with leronlimab in its Phase 2 trial for NASH (nonalcoholic steatohepatitis) open label. The Phase 2 trial for 90 patients is designed to test whether leronlimab may inhibit the devastating liver fibrosis...

CYDY - CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells After Leronlimab Induction or at Baseline; 12-month PFS Co

VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today updated results from its...

CYDY - CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.

VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today preliminary results from...
CYDY - CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum

Activist Group Failed to Submit its Proxies Without Activist Group’s Proxies, Annual Meeting Lacked Quorum CytoDyn Inc. (OTCQB: CYDY) (the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...

CYDY - CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November VANCOUVER, Washington, Oct. 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CC...

CYDY - Two Virtual Investor Conferences the Small Cap Investor should not avoid.

MIAMI, Oct. 26, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 19 th Emerging Growth Conference. The Em...
CYDY - CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil

Based on previous strong sub-population analysis in CD12 trial, CytoDyn intends to file for an EUA when interim analysis of 127 patients is completed VANCOUVER, Washington, Oct. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage ...

CYDY - CytoDyn to Hold Webcast and Live Q/A on October 26

VANCOUVER, Washington, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D.,...

CYDY - CytoDyn Announces Delaware Court Has Denied Activist Group's Motion to Prevent Annual Meeting from Taking Place

2021 Annual Meeting Will be Held as Scheduled on October 28, 2021 CytoDyn Urges Shareholders to Vote on Company’s BLUE Proxy Card to Ensure their Vote Counts All Proxies and Votes in Favor of the Activist Group’s Nominees Will be Disregarded Cyt...
Previous 10 Next 10